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"The Role of Antibodies in Liver Graft-Induced Tolerance in Mice: 
: Passive Transfer of Serum and Effect of Recipient B-Cell Depletion 
U. Dahmen. H. Sun. Y. Li. F. Fu. AJ. Demetris, T.E. Starzl, S. Qian, and J.J. Fung 
MOUSE liver allografts are spontaneously accepted 
, _ . without immunosuppression and induce donor-spe-
'c:ific acceptance of subsequently transplanted skin or heart 
allografts 1 despite various degrees of MHC incompatibility. 
; This in vivo tolerance is associated with donor-specific 
~ reactivity in vitro, a phenomenon called "split tolerance."2 
tTherefore. clonal deletion is unlikely to be the explanation 
!'of graft acceptance in this model. 
The same phenomenon3- b has been observed in some rat 
.strain combinations. In the DA into PVG strain comb ina-
• 'lion, the liver is spontaneously accepted.3 whereas other 
· organs. such as kidney. heart. or skin. are rapidly rejected. 
A liver allograft in the rat is able to overcome the effects of 
· priming by donor antigen and to convert a state of immu-
nological memory into one of specific transplantation tol-
, crance as demonstrated by reversal of ongoing heart and/or 
, akingraft rejection. 1.4 In the rat model. liver graft-induced 
· tolerance (LGT) has been attributed to cellular factors. 
, IUch as selective clonal deletion.7- 9 and development of 
" IUppressor cells. 1O - 12 as well as humoral factors. One 
popular explanation for these findings is the release of 
, , IOluble donor class I antigen by the liver allograft. which in 
aeparate experiments has been shown to prolong modestly 
allograft survival upon passive transfer. 13- 15 Antidonor 
class II antibodies were shown to exert an even more 
-powerful effect. 16 - 18 
In this study, we tested the role of antibodies in LGT in 
the mouse model by analysing the biological activity of 
aerum from liver-grafted mice (> 100 days) and compared it 
to sera from heart and skin graft recipients using in vivo 
(serum transfer) and in vitro (MLR and CML) assays. 
MATERIALS AND METHODS 
Mice 
Ten- to 12-week-old. male C57BVlO (B1O) (H-2h) and C3H/NeJ 
(H-24) mice, purchased from Jackson Laboratory (Bar Harbor. 
Me), were used as donors and recipients for all experiments. 
Animals were housed in the pathogen-free facility of the University 
of Pittsburgh Medical Center according to NIH guidelines. 
Surgical Procedures 
Uver transplantation was performed according to Qian et allY and 
liver graft function assessed by daily monitoring. Heans were 
transplanted heterotopically into the abdomen. adapting the tech-
Dique from Ono and Lindsay.~o Skin grafts were performed by 
placing a full-thickness graft (8 x !l mm) from the tail of the donor 
on the reCipients dorsal side by the method of Billingham et al. ~ I 
Serum was obtained and pooled from serial blood samples (> 100 
clays after transplantation) and stored at - 20°C until use. 
In Vivo S-Cell Depletion 
Neonate C3H/HeJ mice were intraperitoneally injected with )()() 
j.Lg of purified polyclonal rabbit anti-mouse IgM j.L-chain within 12 
hours after birth and then of 100 j.Lg once a week from the age of 
14 days.22 Anti-lgM treatment resulted in complete suppression of 
B-cell development. documented bv the absence of surface Jg and 
B220-Ag+ cells (flow cytometric analysis) and the lack of lipopoly-
saccharide-induced mitogenic responses of spleen and peripheral 
blood mononuclear cells.22 
In Vitro Assays 
To assess the inhibitory effect of serum from LGT. such serum was 
used in standard MLR assays. C3H (0.75%) or LGT (0.75'7r) serum 
or serum from the recipients of heart or skin graft. respectively. the 
IgG fraction was added to 2.5 x )().I cells in round-bottom plates in 
a final volume of 200 j.LL of supplemented DMEM medium and 
cultured for 3 to 5 days at 10% CO~. The IgG fraction of serum was 
obtained by affinity purification over a Protein G column and low 
pH elution. 
The inhibitory effect of serum on cytotoxicity was tested by 
preincubating 5 x 10" 51 Chromium-labeled Con A blasts with 5 j.LL 
of either serum for 1 hour. A total of 5 x 105 in vitro-sensitized 
C3H effector cells were then incubated with these target cells for 4 
hours and 100 j.LL of supernatant measured in a gamma-counter. 
Serum Transfer 
The enhancing effect of LGT was studied by passive transfer of 200 
j.LL of serum IV immediately after transplanting a BIO heart to a 
C3H recipient. Functioning of the heart was monitored by daily 
palpation through the abdominal wall. Rejection was defined by the 
cessation of the cardiac impulse and confirmed hy exploration and 
histological examination. 
RESULTS 
In contrast to the rat model. transfer of serum from LGT mice 
resulted in consistent. but not donor-specific prolongation of 
heart graft survival from 9 to 15 days. Moreover. this effect was 
not liver-specific because serum from skin-grafted mice 
achieved the same results (Table I). When serum from LGT 
mice was used in a mixed lymphocyte culture (MLR), it 
suppressed the proliferative activity to the same extent as 
serum from heart- or skin-grafted mice (about 50%). there-
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Table 1. Enhancing Activity of Serum From LIver 
Graft-Tolerant Mice on Heart Graft Survival 
None 
C3H 
Serum 
OlT B10 -+ C3H 
Skin B10 -+ C3H 
OlT BAlB/c .... C3H 
Skin BAlB/c -+ C3H 
Graft SUrvIVal (days + SO) 
7.4 + 0.40 
9.0:: 0.45 
15.2:!: 1.10 
14.S:: 0.73 
13.2:!: 1.24 
15.2 :!: 2.06 
fore this inhibition was not donor-specific. Cytolytic activity in 
the CML was also nonspecificauy reduced by half when the 
target cells were pre incubated with serum from either LOT or 
skin grafted mice. This nonspecific immunosuppressive activ-
ity was largely contained within the immunoglobulin-rich 
fraction of the serum. 
We further tested the role of antibodies and B cells in 
liver graft acceptance by performing liver allografting in 
B-cell-depleted recipients. which are defective in produc-
ing antibody upon immune stimulus. Despite the paucity of 
antibody-producing B cells in the depleted recipients 
«5%). the rate of spontaneous long-term survival (> 100 
days) in B-cell-depleted animals (five of eight = 62.5%) 
was similar to that in naive recipients (eight of ten = 80%, 
P > .05), as demonstrated in Table 2. 
DISCUSSION 
In contrast to profound23-26 effects in the rat. serum from 
LOT mice showed only modest and nonspecific enhance-
ment of heart allograft survival of about 6 days. Moreover, 
this property was not specific to LOT serum but was also 
observed with serum from murine skin or heart allograft 
recipients. In both models the in vivo observations were 
strengthened by the results of the in vitro studies. Strong 
and donor-specific inhibitory effects on proliferation assays 
were demonstrated in the rat model,27 whereas the inhibi-
tory effect on proliferation and cytotoxicity in the mouse 
model was not donor-specific and not unique to the LOT 
serum. In both models, the inhibitory effect could be 
attributed to IgO fraction of the serum. 
Although a liver graft can induce in vivo tolerance in 
select strain combinations in the rat and is a more general 
phenomenon in the mouse, the role of B cells, their 
production of antibodies. and their integrative effect in the 
immune network seem to follow different mechanisms. 
Using B-cell-depleted recipients. which are defective in 
producing antibody upon immune stimulation. is the ulti-
mate way to analyse the role of antibodies in LOT.22 Such 
a model has already been used to study the importance of 
Table 2. Liver Graft Survival in B-Cell-Depleted Recipients 
Recipients 
C3H (n = 10) 
C3W B (n = 8) 
Survival TIme (Days) 
8. 19, >120 (xS) 
12, 16, 16. >120 (x5) 
Long-Term Survival (%) 
80.0% 
62.5% 
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recipient antibody production on skin allograft rejection in 
mouse.28 In our model, long-term survival was achieved in 
five of eight recipients compared to eight of ten controls: 
the allograft loss in both possibly related to large liver 
infarcts observed on autopsy. 
Since tolerance to liver allograft could be induced in 
B-cell-depleted mice and the "immunosuppressive" activ-
ity of the serum was nonspecific. we conclude that mecha-
nisms other than anti donor antibody production by recipi-
ent B cells plays the pivotal role in liver graft-induced 
tolerance. Other studies in the mouse model,l reporting the 
association between the tolerance phenomenon and donor 
hematolymphoid chimerism. relate the tolerance induction 
to the incorporation of a functional fragment of the donor 
immune components into the recipient immune system. 
REFERENCES 
1. Qian S, Demetris AJ. Murase N. et al: Hepatoiogy 19:916, 1994 
2. Dahmen U, Qian S. Rao A. et al: Transplantation (in press) 
3. Kamada N. Davies HS. Wright DGD. et al: Transplantation 
4:29, 1980 
4. Kamada N. Davies HS. Roser B: Nature 292:840. 1991 
5. Kamada N, Wright DGD: Transplantation 38:217, 1984 
6. Kamada N. Yamaguchi A. Ohuchi Y, et al: Transplant Proc 
21:433. 1989 
7. Davies HS. Kamada N. Roser 81: Transplant Proc 15:831. 1983 
8. Kamada N. Shinomiya T: Immunology 55:85, 1985 
9. Kamada N. Teramoto K. Bacuerito A. et al: Transplantation 
46:165, 1988 
10. Yoshimura S. Gotoh S. Kamada N: Clin Exp Immunol 
85:121, 1991 
11. Yamaguchi A. Yamadera H. Matsuda M. et al: Transplant 
Proc 13:866, 1991 
12. Gotoh S, Kamada N. Kim Y. et al: Transplant Proc 23:2017. 
1991 
13. Sumimoto R, Kamada N: Transplant Proc 23:86. 1991 
14. Sumimoto R. Kamada N: Transplantation 50:678. 1990 
15. Sumimoto R. Kamada N: lmmunol Lett 26:81. 1990 
16. Kamada N. Shinomiya T: Transplantation 42:7, 1986 
17. Kamada N, Shinomiya T. Tamak T, et al: Transplantation 
42:581, 1986 
18. Bacquerito A. Kamada N. Hart J. et al: Transplant Proc 
22:2020, 1990 
19. Qian S. Fung JJ, Demetris AJ. et al: Transplantation 52:562. 
1991 
20. Ono K. Lindsey ES: J Thorac Cardiovasc Surg 7:225. 1969 
21. Billingham RE, Brent L. Medawar PB: Nature 172:603, 1953 
22. Cerny A, Hugin AW. Sutlers S. et al: Cell Bioi 53:301. 1985 
23. Kamada N. Yamaguchi A. Yoshima S. et al: Transplant Proc 
22:1971. 1990 
24. Kamada N. Sumimoto R. Bacquerito A. et al: Immunology 
64:315, 1988 
25. Yamaguchi A. Kamada N: Immunology 72:79. 1991 
26. Sumimoto R. Kamada N: 21:431. 1989 
27. Tschuchimoto S, Kakita A. Uchiro 1. et al: Transplant Proc 
14:3064. 1987 
28. Cernv A. Ramseier H. Bazin H. et al: Transplantation 
45:2222. 1988 
.'~ 
.:; 
